|
No. of patients
|
119
|
132
|
–
|
|
Median age, years (range)
|
28 (14–54)
|
33 (16–56)
|
.127
|
|
Sex, no. (%)
| | |
.448
|
|
Male/female
|
65 (54.6)/54 (45.4)
|
65 (49.2)/67 (50.8)
| |
|
Underlying diseases, (%)
| | |
.731
|
|
AML
|
54 (45.4)
|
57 (43.2)
| |
|
ALL
|
55 (46.2)
|
60 (45.4)
| |
|
ALAL
|
10 (8.4)
|
15 (11.4)
| |
|
Disease stage at transplants, (%)
| | |
.447
|
|
Primary induction failure
|
58 (48.7)
|
57 (43.2)
| |
|
Relapse refractory
|
61 (51.3)
|
75 (56.8)
| |
|
WBC count at diagnosis, n (%)
| | |
.615
|
|
≥ 30,000 per mm3
|
57 (47.9)
|
59 (44.7)
| |
|
< 30,000 per mm3
|
62 (52.1)
|
73 (55.3)
| |
|
Median BM blasts before conditioning (range)
|
33% (7.0–96.0%)
|
31% (8.0–98.0%)
|
.602
|
|
Genetics, (%)
| | |
.527
|
|
Poor
|
65 (54.6)
|
66 (50.0)
| |
|
Intermediate
|
34 (28.6)
|
45 (34.1)
| |
|
Favorable
|
5 (4.2)
|
8 (6.1)
| |
|
Unknown
|
15 (12.6)
|
13 (9.8)
| |
|
Graft no. (%)
| | |
-
|
|
BM + PBSC
|
119 (100)
|
3 (2.3)
| |
|
PBSC
|
0 (0)
|
129 (97.7)
| |
|
Median MNCs, 108/kg (range)
|
7.36 (3.76–12.80)
|
7.80 (3.52–13.16)
|
.136
|
|
MedianCD34 + count, 106/kg (range)
|
5.65 (1.15–15.16)
|
5.41 (0.98–16.46)
|
.471
|
|
Follow-up time in survivors from transplant, median (range), mouth
|
43.4 (20.5–71.5)
|
41.6 (18.2–72.7)
|
.814
|
